Chordate Medical Holding AB (OSTO:CMH) Research & Development: kr0.00 Mil (TTM As of Jun. 2025)


OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
GF Value kr26.18
! 6 Warning Signs
View Full Analysis

What is Chordate Medical Holding AB Research & Development?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 Research & Development is kr0.00 Mil as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100 and a GF Value™ of kr26.18. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chordate Medical Holding AB's Research & Development for the three months ended in Jun. 2025 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was kr0.00 Mil.

Chordate Medical Holding AB  (OSTO:CMH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chordate Medical Holding AB Research & Development Related Terms

Chordate Medical Holding AB Research & Development Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Research & Development Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Chordate Medical Holding AB (OSTO:CMH) has a Research & Development of kr0.00 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's Research & Development too high?
Chordate Medical Holding AB's current Research & Development is kr0.00 Mil. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Research & Development compare to ABT and SYK?
Chordate Medical Holding AB's Research & Development of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Research & Development of kr0.00 Mil. The stock's GF Value™ is kr26.18, compared to a current price of kr0.16 — trading 99.4% below its estimated fair value. The current Research & Development is kr0.00 Mil. Chordate Medical Holding AB's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Research & Development is kr0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chordate Medical Holding AB (OSTO:CMH) Overvalued in 2026?

Based on GuruFocus' analysis, Chordate Medical Holding AB stock appears to be undervalued. The current stock price of kr0.16 is trading 99.4% below its estimated GF Value™ of kr26.18.

Key valuation signals for OSTO:CMH:

  • Research & Development: kr0.00 Mil
  • GF Value™: kr26.18 vs. price of kr0.16 (99.4% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the OSTO:CMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price
kr26.18
GF Value